Rifampicinによる肺結核治療の臨床的研究 : 第1報予備的研究.重症耐性肺結核に対する治療成績

概要

論文の詳細を見る
Before starting collaborative and controlled clinical trials for Rifampicin (abbrev. RFP), a preliminary study with RFP was carried out to investigate clinical effectiveness and side effects of the drug in 50 pulmonary tuberculosis patients with cavities and drug resistance. As indicated in Table 1, patients with a history of suffering from tuberculosis for more than five years occupied approximately 80% of the total cases, and the patients classified as far advanced by NTA classification amounted to 60%. All patients were culture positive and resistant to at least three of the conventional antituberculous drugs, and 24% of the patients were resistant to nine drugs. RFP was used in addition to the previous drug regimen and was administered for six months.450 mg of RFP were given orally once daily 30 minutes before breakfast.